Levels of signaling molecules called cytokines can be used to identify people with systemic scleroderma (SSc) who are at…
Articles by Marisa Wexler, MS
Acazicolcept (ALPN-101), an experimental therapy that blocks T-cell activation and is being developed by Alpine Immune Sciences, was found…
Among people with systemic scleroderma, education and income are major determinants of perceived functional ability, a new study indicates.
Prometheus Biosciences is planning a clinical trial of its investigational anti-inflammatory and antifibrotic medication PRA023 in people with…
Scleroderma renal crisis (SRC), a rare and severe manifestation of systemic scleroderma, is disproportionately common in Blacks, a new…
Talaris Therapeutics has launched a Phase 2 clinical trial to test its treatment candidate FCR001 for people with diffuse…
A first patient has been enrolled in a pivotal Phase 2b clinical trial testing the safety and effectiveness of HZN-825, …
Children with an extremely rare form of systemic scleroderma tend to experience longer diagnostic delays, are more likely to…
Most scleroderma patients who responded to a U.S.-based online survey report being satisfied with their current medications and are…
A new study being conducted at the University of Pittsburgh is testing the safety and effectiveness of COVID-19 vaccines in…